OBJECTIVES: To review understaging and survival of patients who underwent early versus deferred radical cystectomy (RCX) for high-risk non-muscle invasive bladder cancer (NMIBC; T1 G3). METHODS: The results of 1,521 RCXs including 1,420 for bladder cancer were reviewed: (1) A total of 114 patients with high-risk NMIBC underwent a single TUR-BT followed by immediate RCX to estimate the understaging rate. (2) As much as 260 patients with NMIBC had long-term follow-up before RCX to determine the upgrading and upstaging over time. (3) We compared survival in patients with initial T1 G3 bladder cancer (BC) treated with early RCX (n = 175) versus deferred RCX (n = 99) for recurrent T1 G3. RESULTS: (1) Our understaging rate was 20.2%. (2) Allowing NMIBC to upgrade portents a 19% survival disadvantage. (3) The 10 years cancer-specific survival rate was 78.7% in early and 64.5% in deferred RCX. CONCLUSIONS: Early, as compared to deferred RCX, has a distinct survival advantage for high-risk NMIBC. Patients should be counselled accordingly.
OBJECTIVES: To review understaging and survival of patients who underwent early versus deferred radical cystectomy (RCX) for high-risk non-muscle invasive bladder cancer (NMIBC; T1 G3). METHODS: The results of 1,521 RCXs including 1,420 for bladder cancer were reviewed: (1) A total of 114 patients with high-risk NMIBC underwent a single TUR-BT followed by immediate RCX to estimate the understaging rate. (2) As much as 260 patients with NMIBC had long-term follow-up before RCX to determine the upgrading and upstaging over time. (3) We compared survival in patients with initial T1 G3 bladder cancer (BC) treated with early RCX (n = 175) versus deferred RCX (n = 99) for recurrent T1 G3. RESULTS: (1) Our understaging rate was 20.2%. (2) Allowing NMIBC to upgrade portents a 19% survival disadvantage. (3) The 10 years cancer-specific survival rate was 78.7% in early and 64.5% in deferred RCX. CONCLUSIONS: Early, as compared to deferred RCX, has a distinct survival advantage for high-risk NMIBC. Patients should be counselled accordingly.
Authors: Christoph Wiesner; Jesco Pfitzenmaier; Andreas Faldum; Rolf Gillitzer; Sebastian W Melchior; Joachim W Thüroff Journal: BJU Int Date: 2005-02 Impact factor: 5.588
Authors: Ashish M Kamat; Jason R Gee; Colin P N Dinney; H Barton Grossman; David A Swanson; Randall E Millikan; Michelle A Detry; Tracy L Robinson; Louis L Pisters Journal: J Urol Date: 2006-03 Impact factor: 7.450
Authors: Barthold Ph Schrier; Maarten P Hollander; Bas W G van Rhijn; Lambertus A L M Kiemeney; J Alfred Witjes Journal: Eur Urol Date: 2004-03 Impact factor: 20.096
Authors: Francesco Soria; Francesca Pisano; Paolo Gontero; J Palou; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; J A Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; R Sylvester Journal: World J Urol Date: 2018-08-31 Impact factor: 4.226
Authors: J Palou; F Pisano; R Sylvester; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; A J Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E K Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; P Gontero Journal: World J Urol Date: 2018-05-02 Impact factor: 4.226
Authors: Guido Dalbagni; Kinjal Vora; Matthew Kaag; Angel Cronin; Bernard Bochner; S Machele Donat; Harry W Herr Journal: Eur Urol Date: 2009-07-17 Impact factor: 20.096
Authors: Nico C Grossmann; Pawel Rajwa; Fahad Quhal; Frederik König; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Satoshi Katayama; Reza Sari Motlagh; Christian D Fankhauser; Agostino Mattei; Marco Moschini; Piotr Chlosta; Bas W G van Rhijn; Jeremy Y C Teoh; Eva Compérat; Marek Babjuk; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat; Benjamin Pradere Journal: Eur Urol Open Sci Date: 2022-04-01